<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02467504</url>
  </required_header>
  <id_info>
    <org_study_id>hrIL-2 RA</org_study_id>
    <nct_id>NCT02467504</nct_id>
  </id_info>
  <brief_title>Low-dose Recombinant Human IL-2 for the Treatment of Rheumatoid Arthritis</brief_title>
  <official_title>A Randomized, Double Blind, Placebo-controlled Pilot-study to Evaluate Efficacy and Safety of Low-dose hrIL-2 in the Treatment of Methotrexate (MTX)-Naive Patients With Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Monash University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing ShuangLu Pharmaceutical Co., Ltd.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rheumatoid arthritis (RA) is an immune-mediated inflammatory disease, characterized by
      symmetric poly-arthritis usually involving the small joints of the hands and feet. In
      addition, various extra-joint manifestations may develop. Several immunomodulating agents
      have been attempted in the treatment of RA without achieving satisfactory results.
      Dysfunction of regulatory T (Treg) cells has been detected in diverse autoimmune diseases,
      which can be promoted by interleukin-2 (IL-2). The investigators hypothesized that low-dose
      IL-2 could be a novel therapy in active RA patients. This clinical study will test the
      efficacy and safety of low dose IL-2 treatment in RA. The investigators perform a
      single-centre, double-blind pilot trial with hrIL-2 in RA. The investigators evaluate the
      effectiveness and safeness of low-dose hrIL-2 for RA by randomized controlled study (hrIL-2
      (N = 23) + Methotrexate (MTX)+ Loxoprofen versus placebo+MTX + Loxoprofen group (N = 24)).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each RA patients (n=47) with DAS&gt;3.2 received low-dose IL-2+MTX+ Loxoprofen or placebo+MTX +
      Loxoprofen (active group: placebo group =1:1, 1 million units every other day subcutaneously
      (hrIL-2 1×106, ip, Qod) for a period of 14 days. After a 14-day rest, another cycle started)
      for 3 cycles. The end points were safety and clinical and immunologic response.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2015</start_date>
  <completion_date type="Actual">August 31, 2017</completion_date>
  <primary_completion_date type="Actual">January 15, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving DAS28 Remission.</measure>
    <time_frame>week 24</time_frame>
    <description>DAS 28 remission is defined by a disease activity score (28 joint) calculated using the erythrocyte sedimentation rate (DAS28-ESR) of less than 2.6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Meeting the American College of Rheumatology 20% Response Criteria</measure>
    <time_frame>week 12, week 24</time_frame>
    <description>The assessments are based on a 20% or greater improvement from Baseline in the number of tender joints, a 20%, or more improvement in the number of swollen joints, and a 20% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Change From Baseline of Clinical Disease Activity Index (CDAI)</measure>
    <time_frame>week 12, week 24</time_frame>
    <description>Clinical Disease Activity Index(CDAI), the minimum is 0, the maximum is 76. higher scores mean a worse outcome.
The change of from baseline of CDAI, the minimum is -76, the maximum is 76. higher scores mean a worse outcome.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The Change From Baseline of Simplified Disease Activity Index (SDAI)</measure>
    <time_frame>week 12, week 24</time_frame>
    <description>Simplified Disease Activity Index(SDAI). the minimum is 0, the maximum is 96. higher scores mean worse outcome.
The change from baseline of SDAI. the minimum is -96, the maximum is 96. higher scores mean worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events</measure>
    <time_frame>Up to week 24</time_frame>
    <description>adverse events includes injection site reactions, influenza-like symptoms, infection, fever, tumor, cardiovascular event, drug-induced liver and kidney damage.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of CD4+ Treg Cells</measure>
    <time_frame>week 12, week 24</time_frame>
    <description>analysis regulatory CD4+ T(Treg) cells before and during IL-2 treatment. P values&lt;0.05 are considered statistically significant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving DAS28 Low Disease Activity.</measure>
    <time_frame>week 12, week 24</time_frame>
    <description>Low disease activity is defined by a disease activity score (28 joint) calculated using the erythrocyte sedimentation rate (DAS28-ESR) of less than 3.2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving a Good or Moderate European League Against Rheumatism (EULAR) Response</measure>
    <time_frame>week 12, week 24</time_frame>
    <description>Good response is defined as: DAS28-ESR ≤ 3.2 and decrease from Baseline by &gt; 1.2.
moderate response is defined as achievement of one of the following: DAS28-ESR ≤ 3.2 and decrease from Baseline &gt; 0.6 and ≤ 1.2 DAS28-ESR &gt; 3.2 and ≤ 5.1 and decrease from Baseline &gt; 0.6 DAS28-ESR &gt; 5.1 and decrease from Baseline &gt;1.2.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting the American College of Rheumatology 50% Response Criteria</measure>
    <time_frame>week 12, week 24</time_frame>
    <description>The assessments are based on a 50% or greater improvement from Baseline in the number of tender joints, a 50%, or more improvement in the number of swollen joints, and a 50% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting the American College of Rheumatology 70% Response Criteria</measure>
    <time_frame>week 12, week 24</time_frame>
    <description>The assessments are based on a 70% or greater improvement from Baseline in the number of tender joints, a 70%, or more improvement in the number of swollen joints, and a 70% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Meeting the 2011 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Remission Criteria Simplified for Clinical Practice</measure>
    <time_frame>week 12, week 24</time_frame>
    <description>The 2011 ACR/EULAR remission criteria simplified for clinical practice is defined as:Tender Joint Count (TJC) ≤ 1, Swollen Joint Count (SJC) ≤ 1 and Patient's Global Assessment of Disease Activity (PtGADA) ≤ 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change From Baseline of a Health Assessment Questionnaire- Disability Index (HAQ-DI)</measure>
    <time_frame>week 12, week 24</time_frame>
    <description>The domains of the HAQ-DI are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. The total score ranges from 0 to 3 with lower scores meaning lower disability.
The change from baseline of HAQ-DI, minimum is -3, the maximum is 3. higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Scores of SF-36 Quetionnaire</measure>
    <time_frame>week 12, week 24</time_frame>
    <description>Score ranging from 0 to 100 with higher scores a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]</measure>
    <time_frame>week 24</time_frame>
    <description>The Arthritis interference in the last month with work productivity is measured on a scale that ranges from 0 (no interference) to 10 (complete interference). The Arthritis interference in the last month with household work productivity is measured on a scale that ranges from 0 (no interference) to 10 (complete interference).higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Erythrocyte Sedimentation Rate (ESR)</measure>
    <time_frame>week 12, week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C Reactive Protein (CRP)</measure>
    <time_frame>week 12, week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change From Baseline of Patient's Global Assessment of Disease Activity (PtGADA)</measure>
    <time_frame>week 12, week 24</time_frame>
    <description>VAS score from 0 to 100 for Patient's Global Assessment of Disease Activity Higher scores mean a worse outcome. The change from baseline of PtGADA, the minimum is -100, the maximum is 100. Higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change From Baseline of Physician's Global Assessment of Disease Activity (PhGADA)</measure>
    <time_frame>week 12, week 24</time_frame>
    <description>VAS score from 0 to 100 for Physician's Global Assessment of Disease Activity higher scores mean a worse outcome. The change from baseline, the minimum is -100, the maximum is 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Change From Baseline of Patient's Assessment of Arthritis Pain (PtAAP)</measure>
    <time_frame>week 12, week 24</time_frame>
    <description>VAS score from 0 to 100 for Patient's Assessment of Arthritis Pain higher scores mean a worse outcome. The change from baseline of PtAAP, the minimum is -100, the maximum is 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]-2</measure>
    <time_frame>week 24</time_frame>
    <description>In the last month, number of work days missed, number of work days with reduced productivity. In the last month, number of days with no household work, number of days with reduced household work productivity, number of days with hired outside help, number of days missed of family/social/leisure activities in the last month.higher scores mean a worse outcome.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hrIL-2 active</intervention_name>
    <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection)</description>
    <arm_group_label>Experimental</arm_group_label>
    <other_name>Human recombinant IL-2</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>hrIL-2 placebo</intervention_name>
    <description>hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)</description>
    <arm_group_label>Placebo Comparator</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MTX</intervention_name>
    <description>Methotrexate (oral administration)</description>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Folic Acid</intervention_name>
    <description>Folic Acid (oral administration)</description>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Loxoprofen</intervention_name>
    <description>Loxoprofen (oral administration)</description>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_label>Placebo Comparator</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female ≥18 and ≤70 years of age at time of screening

          -  Diagnosed with rheumatoid arthritis

          -  Must have active disease with DMARDs (Disease Modifying Anti-Rheumatic Drugs) except
             MTX, the doses had been stable for at least 3 months before baseline

          -  Moderate or severe rheumatoid arthritis during screening, as defined by a disease
             activity score (28 joint) calculated using the C-reactive protein formula (DAS28-ESR)
             &gt; 3.2

          -  Have given written informed consent

        Exclusion Criteria:

          -  Patient presenting or having a history of other inflammatory joint disease

          -  Patient with ongoing or previous Stevens-Johnson syndrome, toxic epidermal necrolysis
             or erythema multiforme

          -  Patient with significantly impaired bone marrow function or significant anaemia,
             leucopenia or thrombocytopenia due to causes or other than active rheumatoid arthritis

          -  Persistent infection or severe infection within 3 months before enrollment,

          -  Uncontrolled hypertension, uncontrolled diabetes, unstable ischemic heart disease,
             active inflammatory bowel disease, active peptic ulcer disease, terminal illness or
             other medical condition which, in the opinion of the investigator, would put the
             patient at risk to participate in the study,

          -  Clinically relevant cardiovascular, hepatic, neurological, endocrine, or other major
             systemic disease making implementation of the protocol or interpretation of the study
             results difficult

          -  Severe hypoproteinemia (e.g., in case of severe liver disease or nephrotic syndrome)
             with serum albumin &lt; 30 g/L

          -  Moderate or severe impairment of renal function, as known by serum creatinine &gt;
             133μmol/L (or 1.5 mg/dl)

          -  Patient with history of recent and clinically significant drug or alcohol abuse

          -  Impairment of liver function or persisting ALT (SGPT) elevations of more than 2-fold
             the upper limit of normal

          -  Known HIV positive status

          -  Known positive serology for hepatitis B or C

          -  Patient with hypersensitivity to any of the excipients in the tablets of methotrexate

          -  Pregnancy

          -  Breastfeeding

          -  Women of childbearing potential, except if they fulfill specific conditions,

          -  Men wishing to father children during the course of the study or within the 24 months
             thereafter (or 3 month with the washout procedure)

          -  Patient with a congenital or acquired severe immuno-deficiency, a history of cancer or
             lymphoproliferative disease, or any patient who has received total lymphoid
             irradiation.

          -  Enrollment in any other clinical trial involving off-label use of an investigational
             drug or device, or enrollment in any other type of medical research

          -  Any active infection (including chronic or localized infections) for which
             anti-infectives were indicated within 28 days prior to first investigational product
             dose

          -  BMI(body mass index) under 18.5 kg/m2 or more than 30 kg/m2

          -  The above information is not intended to contain all considerations relevant to a
             patient's potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhanguo Li, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Institute of Rheuamotology and Immunology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Rheumatology and Immunology, Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>June 4, 2015</study_first_submitted>
  <study_first_submitted_qc>June 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <results_first_submitted>September 9, 2018</results_first_submitted>
  <results_first_submitted_qc>July 31, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 9, 2019</results_first_posted>
  <last_update_submitted>July 31, 2019</last_update_submitted>
  <last_update_submitted_qc>July 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>Zhanguo Li</investigator_full_name>
    <investigator_title>Dept. Rheumatology and immunology,Peking University People's Hospital</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Loxoprofen</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Experimental</title>
          <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 active: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
        </group>
        <group group_id="P2">
          <title>Placebo Comparator</title>
          <description>hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 placebo: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Experimental</title>
          <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 active: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
        </group>
        <group group_id="B2">
          <title>Placebo Comparator</title>
          <description>hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 placebo: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="47"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.6" spread="10.9"/>
                    <measurement group_id="B2" value="56.4" spread="9.9"/>
                    <measurement group_id="B3" value="54.5" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex/Gender, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Sex</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="23"/>
                    <count group_id="B2" value="24"/>
                    <count group_id="B3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving DAS28 Remission.</title>
        <description>DAS 28 remission is defined by a disease activity score (28 joint) calculated using the erythrocyte sedimentation rate (DAS28-ESR) of less than 2.6</description>
        <time_frame>week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 active: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 placebo: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving DAS28 Remission.</title>
          <description>DAS 28 remission is defined by a disease activity score (28 joint) calculated using the erythrocyte sedimentation rate (DAS28-ESR) of less than 2.6</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.530</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Meeting the American College of Rheumatology 20% Response Criteria</title>
        <description>The assessments are based on a 20% or greater improvement from Baseline in the number of tender joints, a 20%, or more improvement in the number of swollen joints, and a 20% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).</description>
        <time_frame>week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 active: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 placebo: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Meeting the American College of Rheumatology 20% Response Criteria</title>
          <description>The assessments are based on a 20% or greater improvement from Baseline in the number of tender joints, a 20%, or more improvement in the number of swollen joints, and a 20% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.315</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Change From Baseline of Clinical Disease Activity Index (CDAI)</title>
        <description>Clinical Disease Activity Index(CDAI), the minimum is 0, the maximum is 76. higher scores mean a worse outcome.
The change of from baseline of CDAI, the minimum is -76, the maximum is 76. higher scores mean a worse outcome.</description>
        <time_frame>week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 active: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 placebo: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline of Clinical Disease Activity Index (CDAI)</title>
          <description>Clinical Disease Activity Index(CDAI), the minimum is 0, the maximum is 76. higher scores mean a worse outcome.
The change of from baseline of CDAI, the minimum is -76, the maximum is 76. higher scores mean a worse outcome.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.5" lower_limit="-22" upper_limit="-11"/>
                    <measurement group_id="O2" value="-11" lower_limit="-17.5" upper_limit="-7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.0" lower_limit="-19.0" upper_limit="-9.7"/>
                    <measurement group_id="O2" value="-8.0" lower_limit="-16.9" upper_limit="-3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.018</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>The Change From Baseline of Simplified Disease Activity Index (SDAI)</title>
        <description>Simplified Disease Activity Index(SDAI). the minimum is 0, the maximum is 96. higher scores mean worse outcome.
The change from baseline of SDAI. the minimum is -96, the maximum is 96. higher scores mean worse outcome.</description>
        <time_frame>week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 active: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 placebo: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline of Simplified Disease Activity Index (SDAI)</title>
          <description>Simplified Disease Activity Index(SDAI). the minimum is 0, the maximum is 96. higher scores mean worse outcome.
The change from baseline of SDAI. the minimum is -96, the maximum is 96. higher scores mean worse outcome.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.0" lower_limit="-23.1" upper_limit="-12.2"/>
                    <measurement group_id="O2" value="-12.1" lower_limit="-19.3" upper_limit="-6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.9" lower_limit="-19.1" upper_limit="-9.8"/>
                    <measurement group_id="O2" value="-9.2" lower_limit="-17.2" upper_limit="-3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.015</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events</title>
        <description>adverse events includes injection site reactions, influenza-like symptoms, infection, fever, tumor, cardiovascular event, drug-induced liver and kidney damage.</description>
        <time_frame>Up to week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 active: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 placebo: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events</title>
          <description>adverse events includes injection site reactions, influenza-like symptoms, infection, fever, tumor, cardiovascular event, drug-induced liver and kidney damage.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>Chi</non_inferiority_desc>
            <p_value>0.474</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of CD4+ Treg Cells</title>
        <description>analysis regulatory CD4+ T(Treg) cells before and during IL-2 treatment. P values&lt;0.05 are considered statistically significant.</description>
        <time_frame>week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 active: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 placebo: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of CD4+ Treg Cells</title>
          <description>analysis regulatory CD4+ T(Treg) cells before and during IL-2 treatment. P values&lt;0.05 are considered statistically significant.</description>
          <units>percentage of CD4+ T cells</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.94" lower_limit="2.18" upper_limit="13.77"/>
                    <measurement group_id="O2" value="6.46" lower_limit="3.71" upper_limit="12.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.84" lower_limit="3.7" upper_limit="10.61"/>
                    <measurement group_id="O2" value="5.37" lower_limit="3.2" upper_limit="7.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <non_inferiority_desc>description of Treg cells in CD4+ T cells</non_inferiority_desc>
            <p_value>0.665</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving DAS28 Low Disease Activity.</title>
        <description>Low disease activity is defined by a disease activity score (28 joint) calculated using the erythrocyte sedimentation rate (DAS28-ESR) of less than 3.2</description>
        <time_frame>week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 active: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 placebo: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving DAS28 Low Disease Activity.</title>
          <description>Low disease activity is defined by a disease activity score (28 joint) calculated using the erythrocyte sedimentation rate (DAS28-ESR) of less than 3.2</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.616</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving a Good or Moderate European League Against Rheumatism (EULAR) Response</title>
        <description>Good response is defined as: DAS28-ESR ≤ 3.2 and decrease from Baseline by &gt; 1.2.
moderate response is defined as achievement of one of the following: DAS28-ESR ≤ 3.2 and decrease from Baseline &gt; 0.6 and ≤ 1.2 DAS28-ESR &gt; 3.2 and ≤ 5.1 and decrease from Baseline &gt; 0.6 DAS28-ESR &gt; 5.1 and decrease from Baseline &gt;1.2.</description>
        <time_frame>week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 active: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 placebo: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving a Good or Moderate European League Against Rheumatism (EULAR) Response</title>
          <description>Good response is defined as: DAS28-ESR ≤ 3.2 and decrease from Baseline by &gt; 1.2.
moderate response is defined as achievement of one of the following: DAS28-ESR ≤ 3.2 and decrease from Baseline &gt; 0.6 and ≤ 1.2 DAS28-ESR &gt; 3.2 and ≤ 5.1 and decrease from Baseline &gt; 0.6 DAS28-ESR &gt; 5.1 and decrease from Baseline &gt;1.2.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.616</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Meeting the American College of Rheumatology 50% Response Criteria</title>
        <description>The assessments are based on a 50% or greater improvement from Baseline in the number of tender joints, a 50%, or more improvement in the number of swollen joints, and a 50% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).</description>
        <time_frame>week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 active: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 placebo: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Meeting the American College of Rheumatology 50% Response Criteria</title>
          <description>The assessments are based on a 50% or greater improvement from Baseline in the number of tender joints, a 50%, or more improvement in the number of swollen joints, and a 50% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>weed 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.200</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Meeting the American College of Rheumatology 70% Response Criteria</title>
        <description>The assessments are based on a 70% or greater improvement from Baseline in the number of tender joints, a 70%, or more improvement in the number of swollen joints, and a 70% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).</description>
        <time_frame>week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 active: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 placebo: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Meeting the American College of Rheumatology 70% Response Criteria</title>
          <description>The assessments are based on a 70% or greater improvement from Baseline in the number of tender joints, a 70%, or more improvement in the number of swollen joints, and a 70% or greater improvement in 3 of the 5 remaining core set measures: Patient's Global Assessment of Disease Activity (PtGADA), Physician's Global Assessment of Disease Activity (PhGADA), Patient's Assessment of Arthritis Pain (PtAAP), physical function as assessed by the Health Assessment Questionnaire - Disability Index (HAQ-DI) and C-Reactive Protein (CRP).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.373</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Meeting the 2011 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Remission Criteria Simplified for Clinical Practice</title>
        <description>The 2011 ACR/EULAR remission criteria simplified for clinical practice is defined as:Tender Joint Count (TJC) ≤ 1, Swollen Joint Count (SJC) ≤ 1 and Patient's Global Assessment of Disease Activity (PtGADA) ≤ 1.</description>
        <time_frame>week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 active: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 placebo: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Meeting the 2011 American College of Rheumatology/ European League Against Rheumatism (ACR/EULAR) Remission Criteria Simplified for Clinical Practice</title>
          <description>The 2011 ACR/EULAR remission criteria simplified for clinical practice is defined as:Tender Joint Count (TJC) ≤ 1, Swollen Joint Count (SJC) ≤ 1 and Patient's Global Assessment of Disease Activity (PtGADA) ≤ 1.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.565</p_value>
            <method>Chi-squared</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change From Baseline of a Health Assessment Questionnaire- Disability Index (HAQ-DI)</title>
        <description>The domains of the HAQ-DI are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. The total score ranges from 0 to 3 with lower scores meaning lower disability.
The change from baseline of HAQ-DI, minimum is -3, the maximum is 3. higher scores mean a worse outcome.</description>
        <time_frame>week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 active: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 placebo: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline of a Health Assessment Questionnaire- Disability Index (HAQ-DI)</title>
          <description>The domains of the HAQ-DI are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities. The total score ranges from 0 to 3 with lower scores meaning lower disability.
The change from baseline of HAQ-DI, minimum is -3, the maximum is 3. higher scores mean a worse outcome.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.63" lower_limit="-0.88" upper_limit="-0.13"/>
                    <measurement group_id="O2" value="-0.38" lower_limit="-0.75" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" lower_limit="-0.88" upper_limit="-0.19"/>
                    <measurement group_id="O2" value="-0.25" lower_limit="-0.63" upper_limit="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.221</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Scores of SF-36 Quetionnaire</title>
        <description>Score ranging from 0 to 100 with higher scores a better outcome.</description>
        <time_frame>week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 active: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 placebo: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
        </group_list>
        <measure>
          <title>The Scores of SF-36 Quetionnaire</title>
          <description>Score ranging from 0 to 100 with higher scores a better outcome.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.29" lower_limit="8.73" upper_limit="29.65"/>
                    <measurement group_id="O2" value="6.90" lower_limit="1.39" upper_limit="16.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.32" lower_limit="11.89" upper_limit="40.85"/>
                    <measurement group_id="O2" value="27.25" lower_limit="16.58" upper_limit="41.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.085</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]</title>
        <description>The Arthritis interference in the last month with work productivity is measured on a scale that ranges from 0 (no interference) to 10 (complete interference). The Arthritis interference in the last month with household work productivity is measured on a scale that ranges from 0 (no interference) to 10 (complete interference).higher scores mean a worse outcome.</description>
        <time_frame>week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 active: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 placebo: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]</title>
          <description>The Arthritis interference in the last month with work productivity is measured on a scale that ranges from 0 (no interference) to 10 (complete interference). The Arthritis interference in the last month with household work productivity is measured on a scale that ranges from 0 (no interference) to 10 (complete interference).higher scores mean a worse outcome.</description>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rate of Arthritis interference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="0" upper_limit="6.75"/>
                    <measurement group_id="O2" value="2" lower_limit="0" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rate of arthritis interference with household work</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="3" upper_limit="10"/>
                    <measurement group_id="O2" value="5" lower_limit="2.25" upper_limit="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.740</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Erythrocyte Sedimentation Rate (ESR)</title>
        <time_frame>week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 active: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 placebo: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Erythrocyte Sedimentation Rate (ESR)</title>
          <units>millimeter/hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3" spread="25.9"/>
                    <measurement group_id="O2" value="36.8" spread="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.6" spread="25.6"/>
                    <measurement group_id="O2" value="28.3" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.881</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C Reactive Protein (CRP)</title>
        <time_frame>week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 active: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 placebo: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
        </group_list>
        <measure>
          <title>C Reactive Protein (CRP)</title>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="20.83"/>
                    <measurement group_id="O2" value="15.32" spread="14.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" spread="9.0"/>
                    <measurement group_id="O2" value="7.8" spread="7.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.422</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change From Baseline of Patient's Global Assessment of Disease Activity (PtGADA)</title>
        <description>VAS score from 0 to 100 for Patient's Global Assessment of Disease Activity Higher scores mean a worse outcome. The change from baseline of PtGADA, the minimum is -100, the maximum is 100. Higher scores mean a worse outcome.</description>
        <time_frame>week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 active: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 placebo: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline of Patient's Global Assessment of Disease Activity (PtGADA)</title>
          <description>VAS score from 0 to 100 for Patient's Global Assessment of Disease Activity Higher scores mean a worse outcome. The change from baseline of PtGADA, the minimum is -100, the maximum is 100. Higher scores mean a worse outcome.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.5" lower_limit="-76.4" upper_limit="-29.5"/>
                    <measurement group_id="O2" value="-33.3" lower_limit="-66.7" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.1" lower_limit="-75.0" upper_limit="-35.4"/>
                    <measurement group_id="O2" value="-33.3" lower_limit="-62.5" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.055</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change From Baseline of Physician's Global Assessment of Disease Activity (PhGADA)</title>
        <description>VAS score from 0 to 100 for Physician's Global Assessment of Disease Activity higher scores mean a worse outcome. The change from baseline, the minimum is -100, the maximum is 100.</description>
        <time_frame>week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 active: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 placebo: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline of Physician's Global Assessment of Disease Activity (PhGADA)</title>
          <description>VAS score from 0 to 100 for Physician's Global Assessment of Disease Activity higher scores mean a worse outcome. The change from baseline, the minimum is -100, the maximum is 100.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-58.3" lower_limit="-76.4" upper_limit="-47.2"/>
                    <measurement group_id="O2" value="-44.4" lower_limit="-57.1" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.1" lower_limit="-66.7" upper_limit="-33.3"/>
                    <measurement group_id="O2" value="-25.0" lower_limit="-44.4" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.039</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Change From Baseline of Patient's Assessment of Arthritis Pain (PtAAP)</title>
        <description>VAS score from 0 to 100 for Patient's Assessment of Arthritis Pain higher scores mean a worse outcome. The change from baseline of PtAAP, the minimum is -100, the maximum is 100.</description>
        <time_frame>week 12, week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 active: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 placebo: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
        </group_list>
        <measure>
          <title>The Change From Baseline of Patient's Assessment of Arthritis Pain (PtAAP)</title>
          <description>VAS score from 0 to 100 for Patient's Assessment of Arthritis Pain higher scores mean a worse outcome. The change from baseline of PtAAP, the minimum is -100, the maximum is 100.</description>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.5" lower_limit="-76.4" upper_limit="-29.5"/>
                    <measurement group_id="O2" value="-33.3" lower_limit="-66.7" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>week 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.1" lower_limit="-69.6" upper_limit="-41.5"/>
                    <measurement group_id="O2" value="-27.3" lower_limit="-42.7" upper_limit="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.156</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]-2</title>
        <description>In the last month, number of work days missed, number of work days with reduced productivity. In the last month, number of days with no household work, number of days with reduced household work productivity, number of days with hired outside help, number of days missed of family/social/leisure activities in the last month.higher scores mean a worse outcome.</description>
        <time_frame>week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Experimental</title>
            <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 active: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator</title>
            <description>hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 placebo: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
          </group>
        </group_list>
        <measure>
          <title>Work Productivity Survey - Rheumatoid Arthritis [WPS-RA]-2</title>
          <description>In the last month, number of work days missed, number of work days with reduced productivity. In the last month, number of days with no household work, number of days with reduced household work productivity, number of days with hired outside help, number of days missed of family/social/leisure activities in the last month.higher scores mean a worse outcome.</description>
          <units>days</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>number of work days with reduced productivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" lower_limit="0" upper_limit="20"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>number of work days missed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Household work days missed due to arthritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="10"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days with household work productivity reduced</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15" lower_limit="3" upper_limit="30"/>
                    <measurement group_id="O2" value="12" lower_limit="5" upper_limit="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days with activities missed due to arthritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5" lower_limit="0" upper_limit="7"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days with outside help hired due to arthritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Experimental</title>
          <description>hrIL-2 active (1 million U doses of hrIL-2s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 active: hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
        </group>
        <group group_id="E2">
          <title>Placebo Comparator</title>
          <description>hrIL-2 placebo (1 million U doses of placebo s.c.injection) MTX Folic acid Loxoprofen
hrIL-2 placebo: hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
MTX: Methotrexate (oral administration)
Folic Acid: Folic Acid (oral administration)
Loxoprofen: Loxoprofen (oral administration)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="24"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalized not related to RA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>gastrointestinal disorders</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of RA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fever after injection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site reactions</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Prof. Zhanguo Li</name_or_title>
      <organization>Peking university People's Hospital</organization>
      <phone>+86-13810001444</phone>
      <email>13810001444@163.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

